Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 26;5(1):e000722.
doi: 10.1136/openhrt-2017-000722. eCollection 2018.

Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community

Affiliations

Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community

Wolfgang Lieb et al. Open Heart. .

Abstract

Objective: The residual cardiovascular disease (CVD) risk in individuals on long-term lipid-lowering treatment (LLT) in the general population is not well described.

Methods: We estimated absolute CVD risks by age and sex for different categories of low-density lipoprotein cholesterol (LDL-C) levels, stratified by LLT status, and assessed subclinical carotid atherosclerosis in 3012 Framingham Study participants (mean age, 58.4 years; 55% women) free of CVD. Individuals were categorised into five groups: (1) LDL-C <100 mg/dL without LLT; (2) LDL-C ≥100 mg/dL to <130 mg/dL without LLT; (3) LDL-C <130 mg/dL on LLT; (4) LDL-C ≥130 mg/dL without LLT; and (5) LDL-C ≥130 mg/dL on LLT.

Results: Individuals in groups 3-5 had significantly more carotid atherosclerosis compared with group 1. During follow-up (median, 13.7 years), 548 CVD events occurred. Individuals on LLT (groups 3 and 5) had substantial residual CVD risk (26.7 (95% CI 19.5 to 34.0) and 24.1 (95% CI 16.2 to 31.9) per 1000 person-years, respectively), representing approximately three times the risk for untreated individuals with LDL <100 mg/dL (group 1: 9.0 (95% CI 6.8 to 11.3) per 1000 person-years). Absolute CVD risks rose with age and were slightly greater in men than in women. After adjustment for traditional risk factors, groups 3-5 displayed increased hazards for CVD (HR=1.47, 1.42 and 1.54, respectively) compared with group 1. Further adjustment for carotid atherosclerosis modestly attenuated these results.

Conclusions: There is substantial residual CVD risk in individuals on LLT, compared with participants with optimal LDL-C (<100 mg/dL), even when LDL-C levels <130 mg/dL are reached.

Keywords: LDL; cardiovascular disease; lipids; residual risk; subclinical disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
OR for the binary trait ‘carotid ultrasound abnormality’ in an age- and sex-adjusted model (A), as well as in a multivariable-adjusted model (B), including age, sex, systolic blood pressure, antihypertensive medication, smoking and diabetes mellitus. ‘Carotid ultrasound abnormality’ was defined as (1) increased (≥80th sex-specific percentile) carotid IMT, a combined standardised measure including information from the internal and common carotid arteries, (2) an extreme increase of the common carotid IMT ≥1 mm, or (3) significant stenosis (≥25% narrowing) of the common or internal carotid arteries, consistent with prior publications. IMT, intima media thickness; LDL, low-density lipoprotein; LLT, lipid-lowering treatment; w/out, without.
Figure 2
Figure 2
Survival free of CVD, stratified by LDL group. CVD, cardiovascular disease; LDL, low-density lipoprotein; LLT, lipid-lowering treatment.
Figure 3
Figure 3
HRs for incident CVD by LDL group, adjusted for age, sex, systolic blood pressure, antihypertensive medication, smoking and diabetes mellitus. CVD, cardiovascular disease; LDL, low-density lipoprotein; LLT, lipid-lowering treatment; w/out, without.

References

    1. Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9. - PubMed
    1. Colhoun HM, Betteridge DJ, Durrington PN, et al. . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96. 10.1016/S0140-6736(04)16895-5 - DOI - PubMed
    1. Mihaylova B, Emberson J, Blackwell L, et al. . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90. 10.1016/S0140-6736(12)60367-5 - DOI - PMC - PubMed
    1. Taylor F, Huffman MD, Macedo AF, et al. . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816. - PMC - PubMed
    1. Parish E, Bloom T, Godlee F. Statins for people at low risk. BMJ 2015;351:h3908 10.1136/bmj.h3908 - DOI - PubMed

Publication types

LinkOut - more resources